Lemonex announced the approval of an Investigational New Drug (IND) application by the Ministry of Food and Drug Safety (MFDS) for revolutionary mRNA vaccine candidate, LEM-mR203, which incorporates their pioneering nano-drug delivery technology, DegradaBALL®.
The scope of this clinical trial encompasses the evaluation of safety and immunogenicity in healthy adults with a specific focus on addressing the ongoing Covid-19 pandemic. Distinguished by its unique attribute, LEM-mR203 is the first mRNA vaccine candidate to integrate the proprietary drug delivery platform technology, DegradaBALL-mRNA system.
The current lipid nanoparticle (LNP) technology used in existing mRNA vaccines has problems related to allergic reactions or heart issues like myocarditis. The newly developed DegradaBALL drug delivery technology holds promise in mitigating these concerns, suggesting advancement for mRNA vaccines and therapeutics.
The mRNA vaccines offer an accelerated response due to their rapid development cycle compared to antigen protein vaccines. Nevertheless, the efficacy of mRNA delivery within the body hinges on proficient drug delivery technology.
